MDxHealth (NASDAQ:MDXH) Coverage Initiated by Analysts at Craig Hallum

Investment analysts at Craig Hallum assumed coverage on shares of MDxHealth (NASDAQ:MDXH - Get Free Report) in a research report issued on Thursday, MarketBeat reports. The firm set a "buy" rating and a $8.00 price target on the stock. Craig Hallum's price target points to a potential upside of 233.33% from the stock's previous close.

Separately, Wall Street Zen upgraded shares of MDxHealth to a "hold" rating in a research report on Saturday, May 24th.

MDxHealth Stock Performance

MDxHealth stock traded up $0.13 during midday trading on Thursday, reaching $2.40. 132,356 shares of the company traded hands, compared to its average volume of 90,722. The firm has a market capitalization of $113.50 million, a price-to-earnings ratio of -2.09 and a beta of 1.31. The business has a 50 day moving average of $2.10 and a two-hundred day moving average of $1.88. MDxHealth has a 12 month low of $1.35 and a 12 month high of $3.50. The company has a debt-to-equity ratio of 13.81, a current ratio of 2.00 and a quick ratio of 1.92.

MDxHealth (NASDAQ:MDXH - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.06). MDxHealth had a negative return on equity of 492.11% and a negative net margin of 41.02%. The business had revenue of $24.29 million during the quarter, compared to the consensus estimate of $22.62 million. As a group, research analysts predict that MDxHealth will post -1.15 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in MDXH. FAS Wealth Partners Inc. raised its position in shares of MDxHealth by 49.6% during the 4th quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company's stock valued at $58,000 after purchasing an additional 8,100 shares during the period. Geode Capital Management LLC bought a new stake in shares of MDxHealth during the 4th quarter valued at $25,000. XTX Topco Ltd bought a new stake in shares of MDxHealth during the 4th quarter valued at $63,000. Castleview Partners LLC bought a new stake in shares of MDxHealth during the 1st quarter valued at $48,000. Finally, Delta Investment Management LLC bought a new stake in shares of MDxHealth during the 4th quarter valued at $81,000.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.